Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis
ACS Omega · 03.11.2026 · 11 (43) · 66899-66915
DOI: 10.1021/acsomega.6c06826 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 22.10.2026. Verfasst von Jhonatan Santos de Lima und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento CientÃfico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo, Financiadora de Estudos e Projetos.
Abstract (Originalsprache)
Leishmaniasis remains a major neglected tropical disease with limited therapeutic options and increasing concerns regarding toxicity and drug resistance. Cysteine protease B (CPB), a key virulence factor in Leishmania spp., represents an attractive molecular target for the development of new antileishmanial agents. In this study, we designed and synthesized a series of dipeptidyl nitrile derivatives as reversible covalent CPB inhibitors and evaluated their biological activity in vitro and in vivo. Molecular docking performed in covalent mode demonstrated favorable accommodation of the compounds within the CPB active site, with the benzyl-containing derivatives showing the most favorable interactions. Among the series, compound 1 ((S)-tert-butyl (1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate) exhibited potent inhibition of recombinant LmCPB2.8ΔCTE (IC50 = 4.3 ± 0.2 μM) and strong activity against intracellular amastigotes of Leishmania infantum (EC50 = 3.9 ± 0.5 μM; SI ≈ 77) and Leishmania amazonensis (EC50 = 4.6 ± 1.6 μM; SI ≈ 65), surpassing miltefosine in selectivity. Compound 1 showed no cytotoxicity toward murine macrophages, no hemolytic activity, and good tolerability in the Galleria mellonella model. Oral administration of compound 1 to L. infantum-infected BALB/c mice (0.77 mg/kg/day for 5 days) resulted in a significant reduction in parasite burden in the liver and spleen (≈ 40–55%), even at a 10-fold lower dose than miltefosine. Although alterations in hepatic transaminases were observed, no evidence of renal dysfunction was detected. Collectively, these findings identify dipeptidyl nitriles as promising CPB-targeting scaffolds and position compound 1 as a lead structure for further optimization aimed at enhancing antileishmanial efficacy while minimizing host toxicity.
Autor:innen und Institutionen
- Department of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.
- Department of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.
- Laboratory of Medicinal and Computational Chemistry, Physics Institute of São Carlos, University of São Paulo (USP), São Carlos 13563-120, SP, Brazil.
- Department of Biochemistry and Organic Chemistry, Institute of Chemistry, São Paulo State University (UNESP), Araraquara 14800-060, Brazil.
- Department of Biological Sciences, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.
- Latin American Institute of Life and Nature Sciences, Federal University of Latin American Integration (UNILA), Foz do Iguaçu 85870-650, Brazil.
ORCID-Profile: Jhonatan Santos de Lima, Natalia Caroline Costa Coelho, Rafael Consolin Chelucci, Leonardo Luiz Gomes Ferreira, Adriano Defini Andricopulo, João Victor Marcelino de Souza, Bruna Cardinali Lustri Morgado, Eduardo Maffud Cilli, Jean Leandro Dos Santos, Angela Maria Arenas Velásquez, Marcia Aparecida Silva Graminha
Förderung
- Conselho Nacional de Desenvolvimento CientÃfico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Financiadora de Estudos e Projetos
- Coordenação de Aperfeiçoamento de Pessoal de NÃvel Superior
- Fundação para o Desenvolvimento da UNESP
- Universidade Estadual Paulista
Zitieren
APA
de Lima, J. S., Mela, M. F. D. S., Lopes, J. R., Prates, J. L. B., Coelho, N. C. C., Yagi, A. C. L., Chelucci, R. C., Duarte, S. M., Ferreira, L. L. G., Andricopulo, A. D., Paulino, G. C., de Souza, J. V. M., Morgado, B. C. L., Sanches, P. R. D. S., Cilli, E. M., Dos Santos, J. L., Velásquez, A. M. A., & Graminha, M. A. S. (2026). Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis. ACS Omega, 11(43), 66899-66915. https://doi.org/10.1021/acsomega.6c06826
Vancouver
de Lima JS, Mela MFDS, Lopes JR, Prates JLB, Coelho NCC, Yagi ACL, et al. Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis. ACS Omega. 2026;11(43):66899-66915. doi:10.1021/acsomega.6c06826
BibTeX
@article{deLima2026,
author = {de Lima, Jhonatan Santos and Mela, Michele Ferreira da Silva and Lopes, Juliana Romano and Prates, João Lucas Bruno and Coelho, Natalia Caroline Costa and Yagi, Ana Clara Lunardi and Chelucci, Rafael Consolin and Duarte, Simone Michelan and Ferreira, Leonardo Luiz Gomes and Andricopulo, Adriano Defini and Paulino, Gustavo Chagas and de Souza, João Victor Marcelino and Morgado, Bruna Cardinali Lustri and Sanches, Paulo Ricardo da Silva and Cilli, Eduardo Maffud and Dos Santos, Jean Leandro and Velásquez, Angela Maria Arenas and Graminha, Marcia Aparecida Silva},
title = {Nitrile-Based Leishmania Cysteine Protease B Inhibitors with In Vivo Efficacy against Visceral Leishmaniasis},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {43},
pages = {66899--66915},
doi = {10.1021/acsomega.6c06826}
}
EUVIMED